CLL Overview

Current Publications

Experts Summaries Provide Reference Points for Clinicians

Citations of Useful Overviews

Here are some references to expert articles that should be useful to you and to your CLL doctor. They are recent scholarly articles that summarize the state of our understanding of CLL and recommend approaches to deal with it. If you would like to read any or all of these articles but have trouble locating or gaining access to them, please do write to us and we will be happy to help you.

The articles are all authored by top experts from Mayo Clinic, Ohio State and M. D. Anderson — and available as PDFs.

Risk-adapted Strategies

Experts Summarize the State of CLL Therapy

Where Are We?

Drawing from a group of top-rated experts, Dr. Marco Montillo in Milan has produced an overview of where we are in understanding and treating CLL. Patients and their oncologists should pay close attention to the historical evidence and conclusions presented by this group. Read about it in Risk-adapted Strategies.

Staging is Superseded

The New Think on CLL Is Finally Here

The Dawn of a New Era

An important new review article has been published in the New England Journal of Medicine. The Rai/Binet staging systems have been important in triggering therapy decisions. In this article the authors, who include Dr. Kanti Rai himself, bluntly state that the staging system with its emphasis on watch & wait should be replaced by better methods using modern prognostic indicators. We cover this important article as well as several other related works in The Dawn of a New Era.

Physicians' Corner

Progress in Finding a Cure

Are We There Yet?

Professor Terry Hamblin needs no introduction to CLL patients. His seminal work on the prognostic value of the IgVH gene mutation status has become a cornerstone in the risk stratification of CLL patients. In his article, Are We There Yet?, Dr. Hamblin discusses criteria for initiating treatment as well as what treatment can and cannot do for the patient. He goes on to review the current status of combination chemo-immunotherapy clinical trials. Read this article for a candid assessment of where we are in the campaign to cure CLL.